Please login to the form below

Not currently logged in

Viking Therapeutics

This page shows the latest Viking Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Viking throws down gauntlet in NASH battle

Viking throws down gauntlet in NASH battle

Impressive data in a phase 2 trial caused shares in Viking Therapeutics to almost double yesterday as investors got excited about another candidate for non-alcoholic steatohepatitis (NASH). ... Viking’s VK2809 – a thyroid hormone receptor beta

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    The acquisition for up to $658m (a 59 per cent premium on the pre-bid share price) of the US company, Chelsea Therapeutics, achieves both those goals. ... As a footnote, Ligand this month licensed to what appears to be a new company called Viking

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...